HDAC7 and neoplasm: In NSCLC, histone deacetylase 7 (HDAC7) promotes tumor proliferation and metastasis by activating the β-catenin/FGF18 pathway, suggesting that targeting HDAC7 or its associated signaling cascades may serve as a novel therapeutic strategy (98).